Everything below concerns melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Dyson replied that "[m]y objections to the global warming propaganda are not so much over the technical facts, about which I do not know much, but it's rather against the way those people behave and the kind of intolerance to criticism that a lot of them have." Dyson stated in an interview that the argument with Hansen was exaggerated by The New York Times, stating that he and Hansen are "friends, but we don't agree on everything." Since originally taking an interest in climate studies in the 1970s, Dyson suggested that carbon dioxide levels in the atmosphere could be controlled by planting fast-growing trees. He calculated that it would take a trillion trees to remove all carbon from the atmosphere. In a 2014 interview he said, "What I'm convinced of is that we don't understand climate... It will take a lot of very hard work before that question is settled." Dyson was a member of the academic advisory council of the Global Warming Policy Foundation.
== Adverse effects == The immediate risk is hypoglycemia. The main risk is that the person will die from cancer because IPT does not work. The use of lower than normal doses of chemotherapy can cause drug resistance, which could make future treatment at standard, proven doses ineffective. For some cancers, especially breast and colon cancers, insulin may promote tumor growth.
== Mechanism of action == BDNF binds at least two receptors on the surface of cells that are capable of responding to this growth factor, TrkB (pronounced "Track B") and the LNGFR (for low-affinity nerve growth factor receptor, also known as p75). It may also modulate the activity of various neurotransmitter receptors, including the Alpha-7 nicotinic receptor. BDNF has also been shown to interact with the reelin signaling chain. The expression of reelin by Cajal–Retzius cells goes down during development under the influence of BDNF. The latter also decreases reelin expression in neuronal culture.
Sources: en.wikipedia.org
== Definition == In vitro (Latin for "in glass"; often not italicized in English usage) studies are conducted using components of an organism that have been isolated from their usual biological surroundings. As the name suggests, in vitro experiments, colloquially "test-tube experiments", are traditionally done in glass labware, using test tubes, flasks, Petri dishes, etc. The exact scope of in vitro depends on what is considered to be in vivo (experiments done on whole living beings), and in turn what is considered to be a "whole" living being:
== Production of extracellular metabolites == Metabolites can be divided into two groups: those produced during the growth phase of the organism, called primary metabolites and those produced during the stationary phase, called secondary metabolites. Some examples of primary metabolites are ethanol, citric acid, glutamic acid, lysine, vitamins and polysaccharides. Some examples of secondary metabolites are penicillin, cyclosporin A, gibberellin, and lovastatin.
Amin al-Husayni, president – member of the al-Husayni clan, the Grand Mufti of Jerusalem, and president of the Supreme Muslim Council until his dismissal from that position Raghib al-Nashashibi – member of the Nashashibi clan, which was considered to be political rivals of the al-Husayni clan, and to hold moderate views when compared to the more militant views of the al-Husayni, member of the National Defence Party Jamal al-Husayni – related to Amin al-Husayni and chairman of the Palestine Arab Party, member of the Supreme Muslim Council Yaqub al-Ghusayn – member and representative of the Youth Congress Party, member of the Supreme Muslim Council, deported Abd al-Latif Salah – founder of the National Bloc Husayin al-Khalidi – founder and representative of the Reform Party, deported Awni Abd al-Hadi – leader of the Istiqlal (Independence) Party, who was appointed General Secretary Ahmed Hilmi Pasha – treasurer, deported. Initially, the committee included representatives of the rival Nashashibi and al-Husayni clans. The committee was formed after the 19 April call for a general strike of Arab workers and businesses, which marked the start of the 1936–39 Arab revolt. On 15 May 1936, the committee endorsed the general strike, calling for an end to Jewish immigration; the prohibition of the transfer of Arab land to Jews; and the establishment of a National Government responsible to a representative council. Later it called for the nonpayment of taxes. Raghib al-Nashashibi, of the Nashashibi clan and member of the National Defence Party soon withdrew from the committee.
=== Population structure === The population of P. aeruginosa can be classified in three main lineages, genetically characterised by the model strains PAO1, PA14, and the more divergent PA7. While P. aeruginosa is generally thought of as an opportunistic pathogen, several widespread clones appear to have become more specialised pathogens, particularly in cystic fibrosis patients, including the Liverpool epidemic strain (LES) which is found mainly in the UK, DK2 in Denmark, and AUST-02 in Australia (also previously known as AES-2 and P2). There is also a clone that is frequently found infecting the reproductive tracts of horses.
Sources: en.wikipedia.org
== Phylogeny == Like the potato, tomatoes belong to the genus Solanum, which is a member of the nightshade family, the Solanaceae. That is a diverse family of flowering plants, often poisonous, that includes the mandrake (Mandragora), deadly nightshade (Atropa), and tobacco (Nicotiana), as shown in the outline phylogenetic tree (many branches omitted).
=== Lacrosse bro (Lax Bro) === Lax bro subculture is defined as a laid-back ("chill") lifestyle associated with lacrosse. The bounds of the subculture are loose, but its character traits include "understated confidence that critics call arrogance", long hair known as "lettuce," colorful board shorts, flat-brim baseball hats, and colorful half-calf socks. The bands O.A.R., Dispatch, and Dave Matthews Band are associated with lax bros. Typical lax bro attitude and style are common in middle schools and universities according to a 2012 report in The Boston Globe. Enthusiasts praise the subculture's sense of identity and popularization of a sport indigenous to the United States, while detractors take issue with the "preppie/frat boy image that glorifies elitism and wealth, and values flash over hard work".
=== Muscle involvement === Diagnosing MCTD involves identification of inflammatory myopathy that is histologically and clinically identical to polymyositis (PM). The majority of persons with MCTD do not experience clinical weakness. People with MCTD typically have mild myositis, with normal muscle enzymes and electromyographic results. Some people may be completely asymptomatic. Myositis can be severe and difficult to differentiate from conventional dermatomyositis. Myalgia is a prevalent complaint among patients with MCTD.
== Adverse effects == Mitragyna speciosa may cause many adverse effects, and in November 2017 the FDA issued a public health advisory for the drug. The side effects of kratom appear to be dose-dependent and are more common with doses that exceed 8 g. While the incidence of adverse effects in people who use kratom is unknown, a 2019 review of 935 kratom exposures reported to U.S. poison control centers over a seven-year period listed the following signs and symptoms: agitation (18.6%), tachycardia (16.9%), drowsiness (13.6%), vomiting (11.2%), confusion (8.1%), seizures (6.1%), withdrawal symptoms (6.1%), hallucinations (4.8%), respiratory depression (2.8%), coma (2.3%), and cardiac or respiratory arrest (0.6%). The study also reported two deaths and four cases of neonatal abstinence syndrome. A different 2019 review listed as common side effects: decreased appetite, weight loss, erectile dysfunction, insomnia, sweating, hyperpigmentation, hair loss, tremor, and constipation. Kratom products in the U.S. are commonly used in doses of 2–6 g of dried leaf, and doses exceeding 8 g are relatively uncommon. Given that kratom products may vary greatly in potency, there is no standard dosing system. At relatively low doses (1–5 g of raw leaves), at which there are mostly stimulant effects, side effects include contracted pupils and blushing; adverse effects related to stimulation include anxiety and agitation, and opioid-related effects such as itching, nausea, loss of appetite, and increased urination begin to appear.
A fifth vector is acknowledged to have occurred on 30 May 2007 FDA/USDA press conference, whereby U.S. manufacturers of livestock and shrimp/fish feed have acknowledged adding melamine to their products as a binder. The original Xuzhou Anying wheat gluten was "human grade," as opposed to "feed grade," meaning that it could have been used to make food for humans such as bread or pasta. At least one contaminated batch was used to make food for humans, but the FDA quarantined it before any was sold. The FDA also notified the Centers for Disease Control and Prevention to watch for new patients admitted to hospitals with renal failure. As of April 2007, there were no observed increases in human illnesses, and little human food tested as contaminated. Reports of widespread melamine adulteration in Chinese animal feed have raised the possibility of wider melamine contamination in the human food supply in China and abroad. Despite the widely reported ban on melamine use in vegetable proteins in China, at least some chemical manufacturers continue to report selling it for use in animal feed and in products for human consumption. Said Li Xiuping, a manager at Henan Xinxiang Huaxing Chemical in Henan Province: "Our chemical products are mostly used for additives, not for animal feed.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.